Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE DTPA versus TECHNETIUM TC 99M TSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE DTPA versus TECHNETIUM TC 99M TSC.
DRAXIMAGE DTPA vs TECHNETIUM TC 99M TSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRAXIMAGE DTPA (technetium Tc-99m pentetate) is a radiopharmaceutical that, after intravenous injection, distributes in the extracellular space and is cleared by glomerular filtration. It allows imaging of renal function and structure by emitting gamma radiation detectable by a gamma camera.
Technetium Tc 99m TSC is a radiopharmaceutical that binds to activated leukocytes, primarily neutrophils, via interaction with integrin receptors (e.g., CD11b/CD18), allowing imaging of inflammation and infection.
Diagnostic imaging: 3-5 mCi (111-185 MBq) IV for renal studies; 10-20 mCi (370-740 MBq) IV for lung perfusion imaging.
1-10 mCi (37-370 MBq) intravenously as a single dose for imaging studies; dose depends on indication and imaging protocol.
None Documented
None Documented
Terminal elimination half-life is approximately 1.6 hours (range 1.2-2.0 hours) in patients with normal renal function; prolonged in renal impairment (up to 50 hours in severe cases).
Terminal half-life approximately 6 hours; allows for same-day imaging but requires prompt scanning due to radionuclide decay.
Renal: 95% within 24 hours via glomerular filtration; biliary/fecal: <5%.
Renal: ~50% excreted unchanged in urine within 24 hours; remainder eliminated via hepatobiliary system into feces.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical